002873SZSE

Audit Opinion on the Second Extraordinary Meeting of the Eighth Board of Directors

Xintian Pharmaceutical Co., Ltd.··2 pages

✨ AI Summary

The independent directors reviewed and approved the proposal on the execution of related party transactions in 2025 and the forecast for 2026. The actual 2025 transactions were 32.51% lower than forecast due to reduced service provision. The 2026 forecast is based on business needs, with reduced transactions and adherence to fair market pricing.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Guiyang New Pharmaceutical Co., Ltd. Audit Opinion on the Second Extraordinary Meeting of the Eighth Board of Directors

Guiyang New Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the Second Extraordinary Meeting of the Eighth Board of Directors on March 16, 2026, in a face-to-face format. Three independent directors were entitled to attend, and three independent directors actually attended and voted. The convening of the meeting complied with the relevant provisions of the "Company Law," the "Administrative Measures for Independent Directors of Listed Companies," and other laws, regulations, normative documents, and the "Articles of Association."

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.